Health reform law offers relief in Medicare Part D coverage gap

Traynor, Kate
July 2010
American Journal of Health-System Pharmacy;7/1/2010, Vol. 67 Issue 13, p1049
Academic Journal
The article reports on the gradual closing of the coverage gap that the new U.S. healthcare reform bill offers to participants in the Medicare Part D prescription drug benefit. Under the law, beneficiaries are obliged for 5% of their drug costs while the drug plan pays 15% and Medicare pays 80% when catastrophic coverage becomes available. Moreover, drug manufacturers will be mandated by the law to give Part D enrollees a 50% discount on the cost of covered brand name prescription medications.


Related Articles

  • Industry Developments.  // United States Pharmaceuticals & Healthcare Report;Q2 2010, p32 

    This article presents an outlook for the U.S. pharmaceutical and healthcare industry for 2010-2030. It expects an increase in the overall disease burden in the U.S. through 2030. It cites human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) as the only communicable disease...

  • Can Medicare Save Money for Beneficiaries & Taxpayers Alike? Pollack, Ron // Braille Forum;Jul2013, Vol. 52 Issue 1, p17 

    The article presents questions and answer related to Medicare beneficiaries and taxpayers including whether Medicare Part D coverage gap saves beneficiaries benefited, in what way does Medicare bargain on prescription drugs, and ways for Medicare beneficiaries to save money on prescription drugs.

  • Study: Medicare Part D increases office care.  // Medical Economics;8/25/2011, Vol. 88 Issue 16, p15 

    The article discusses the findings of the study regarding the significance of the implementation of the Medicare Part D in the U.S. It states that the implementation of Part D reduced nondrug medical spending by Medicare beneficiaries who had limited prior drug coverage. It says that the...

  • Will healthcare reform gains outweigh pain? Arnold, Matthew // Medical Marketing & Media;May2011, Vol. 46 Issue 5, p13 

    The article focuses on the impact of the Patient Protection and Affordable Care Act (PPACA) on the pharmaceutical industry in the U.S. It states that the PPACA was signed by U.S. President Barack Obama in 2010 which was supported by the Pharmaceutical Research and Manufacturers of America...

  • Sustaining Medicare's Promise. MANTHOUS, CONSTANTINE A. // Connecticut Medicine;Nov2011, Vol. 75 Issue 10, p619 

    Medicare is projected to face shortfalls by 2024. Structural changes of the program have been discussed, but current healthcare reform proposals have not included modifications that are certain to reduce expenditures. One idea that is gaining political traction is to advance the age of...

  • Health Reform Challenges Biotech Industry. Wechsler, Jill // BioPharm International;Aug2009, Vol. 22 Issue 8, p18 

    The article reports on the challenges posed by health reform to the biotechnology industry in the U.S. It states that the industry is worried that it might be affected by cost control and regulatory changes designed to pay a part of the cost of achieving universal coverage. Proposals for...

  • White House budget would cost pharmas. Arnold, Matthew // Medical Marketing & Media;May2013, Vol. 48 Issue 5, p14 

    The article offers the author's view on the impact of the proposed budget of the federal government on the pharmaceutical industry in the U.S. for 2014. He mentions that it would make pharmaceutical firms pay more in various ways whenever enacted by the Congress which involve mandates on the...

  • The "Other" Health Insurance Reform: Medicare Part D since 2004. Cutler, Neal E. // Journal of Financial Service Professionals;Nov2010, Vol. 64 Issue 6, p22 

    Hindsight now allows us to favorably review the prescription drug coverage provided by Medicare Part D. The goals of the 2006 law were to provide pharmaceutical coverage to seniors who had none and to be well perceived by users of the service. This column explores the extent to which the goals...

  • Obama Policies Reshape Pharma Marketing. Wechsler, Jill // Pharmaceutical Executive;Apr2014, Vol. 34 Issue 4, p12 

    The article discusses the various impacts of U.S. President Barack Obama's health reform policies on the pharmaceutical marketing in the country. It examines the impact of the Affordable Care Act of 2010 (ACA), the planned expansion of electronic health records (EHRs) usage by doctors and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics